Team (TISI) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
26 Dec, 2025Executive summary
Achieved significant operational and financial improvements in 2024, including cost reductions, margin enhancements, and strategic initiatives.
Fourth quarter 2024 revenue was $213.3 million; full year revenue reached $852.3 million.
Gross margin improved to 26.9% in Q4 and 26.2% for the year, driven by pricing, project mix, and cost optimization.
Net loss narrowed to $7.2 million in Q4 and $38.3 million for the year, both significant improvements year-over-year.
Adjusted EBITDA rose 50.5% in Q4 to $14.6 million and 27.7% for the year to $54.3 million.
Financial highlights
Q4 2024 revenue was nearly flat year-over-year, but operating income in both segments increased by 45.4% and 51%.
Q4 gross margin increased by 330 basis points year-over-year; full year gross margin up 170 basis points.
Q4 operating income was $2.2 million, up $11.1 million from Q4 2023; full year operating income was $10.1 million, up $23.4 million.
Cash flow from operations in Q4 was $21.6 million, up $10.5 million year-over-year; free cash flow was $19.6 million, up $11.5 million.
Consolidated net loss for 2024 decreased by almost 50% to $38.3 million.
Outlook and guidance
Expects mid-single-digit revenue growth and at least 15% year-over-year growth in 2025 adjusted EBITDA.
Targeting further progress toward an adjusted EBITDA margin of at least 10%.
Additional annualized cost savings of at least $10 million targeted through expanded optimization initiatives.
Anticipate full impact of recent cost-saving and growth initiatives in 2026.
Latest events from Team
- 2026 meeting covers director elections, compensation, auditor, warrant issuance, and equity plan.TISI
Proxy filing24 Mar 2026 - Revenue, operating income, and adjusted EBITDA rose, margins improved, and debt was reduced.TISI
Q4 202513 Mar 2026 - Margins and cash flow improved in Q2 2024, with full-year growth and guidance reaffirmed.TISI
Q2 20242 Feb 2026 - Q3 2024 revenue and margins improved, but guidance was lowered amid ongoing liquidity and NYSE risks.TISI
Q3 202415 Jan 2026 - Registering 1.45M shares for resale post-$75M private placement, supporting recapitalization.TISI
Registration Filing16 Dec 2025 - Key votes include director elections, auditor ratification, and a charter amendment on director removal.TISI
Proxy Filing2 Dec 2025 - Annual meeting covers director elections, pay, auditor ratification, and governance updates.TISI
Proxy Filing2 Dec 2025 - Flat Q1 revenue, $29.7M net loss, and refinancing set up at least 15% EBITDA growth for 2025.TISI
Q1 202525 Nov 2025 - Q2 revenue rose 8.5% to $248.0M, Adjusted EBITDA up 12.4%, with margin gains and transformation underway.TISI
Q2 202523 Nov 2025